Success Stories: Indian Research Scientist Secures NIW Approval for Cancer Therapeutics Research

Client’s Testimonial:

“I can’t thank enough Chen Group and Belinda for all the help and support. Belinda is the best. She understood the complexity of my situation and provided the best help in a very short time. They are highly skilled and knowledgeable on research in cancer and other diseased conditions to make an overwhelmingly compelling case for the national and global importance of my research. Belinda just needed a rough draft from me that is not even written systematically, not informative fully and organized. She turned that draft into a perfect summary of research and proposed endeavor. Belinda is also thorough in checking consistency, grammatical and technical mistakes in the documents. At the time of preparation, I was going through personal crisis and they understood it and helped me to finish the application in short time with minimal effort from my side. They are very helpful, professional, quick to response and had edited my draft until I am satisfied. I strongly recommend Belinda and Chen group.”

On September 19^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Research Scientist in the field of Biochemistry (Approval Notice).

General Field: Biochemistry

Position at the Time of Case Filing: Research Scientist

Country of Origin: India

State of Residence at the Time of Filing: Virginia

Approval Notice Date: September 19^th, 2025

Processing Time: 28 days (Premium Processing Requested)

Case Summary:

We are pleased to share the EB-2 NIW (National Interest Waiver) approval of a research scientist from India. At the time of filing, he was working in the United States, applying his expertise in molecular biology and biochemistry to advance cancer therapeutics. His publication record, growing citations, and peer recognition demonstrated that he was a strong candidate for NIW approval.

Research with Substantial Merit and National Importance

The client’s proposed endeavor focuses on overcoming drug resistance in cancer by targeting key pathways such as Nrf1 and DDI2, which enable tumor cells to withstand proteasome inhibitors. By developing small-molecule inhibitors and designing effective combination therapies, his work contributes to safer and more successful cancer treatments.

Drug resistance remains responsible for most cancer treatment failures, making his research nationally important. His studies support U.S. initiatives like the Cancer Moonshot by advancing therapies that reduce mortality, improve quality of life, and ease the economic burden of chronic disease.

Well Positioned to Advance the Proposed Endeavor

The client holds a Ph.D. in biochemistry and has authored 11 peer-reviewed journal articles, 5 of them as first or co-first author, published in respected outlets such as ACS Central Science, Journal of Cell Biology, International Journal of Molecular Sciences, and Scientific Reports. His research has been cited more than 650 times by independent researchers worldwide, with multiple articles ranked among the top 10 to 20 percent of most cited in their publication years.

He has also advanced the field through methodological innovations. His work on resveratrol-based compounds, STAT3 regulation, and proteasome function has been adopted in studies of cancer biology, neurodegeneration, and drug discovery, underscoring his influence and credibility.

NIW Approval and Outlook

The I-140 NIW petition was filed on August 22, 2025, upgraded to premium processing, and approved on September 19, 2025. USCIS recognized his scholarly record, citation impact, peer review contributions, and the national importance of his proposed endeavor as sufficient to meet the NIW standard.

With NAILG’s support, the client secured NIW approval and is now well-positioned to continue his biomedical research in the United States. His ongoing work promises to contribute to safer, more effective cancer therapeutics, reinforcing U.S. leadership in life sciences and public health.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.